A Potential New Use for Tocilizumab: Refractory Checkpoint Inhibitor Hepatitis

被引：2
|
作者：
Lyles, Laine [1 ]
Farmer, Reagan [2 ]
Abougergi, Marwan [3 ]
机构：
[1] Univ South Carolina, Prisma Hlth, Columbia, SC 29208 USA
[2] Univ South Carolina, Sch Med Columbia, Columbia, SC USA
[3] Catalyst Med Consulting, Simpsonville, SC USA
来源：
ACG CASE REPORTS JOURNAL | 2023年 / 10卷 / 09期
关键词：
autoimmune hepatitis; drug-induced autoimmune hepatitis; check point inhibitor; chemotherapy; renal cell carcinoma; hepatitis; drug induced liver injury; steroid refractory; tocilizumab; nivolumab; ipilimumab; CANCER;
D O I：
10.14309/crj.0000000000001162
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Immune checkpoint inhibitors are becoming more commonly used for many forms of malignancy. With this class of medications being more heavily used, there has been an associated rise in medication-induced autoimmune hepatitis. This case involves a 35-year-old woman being treated with nivolumab/ipilimumab for renal cell carcinoma who developed a steroid-refractory autoimmune hepatitis.
引用
收藏
页数：3
相关论文
共 50 条
  • [31] THE USE OF TOCILIZUMAB IN A CASE OF BIOLOGIC-REFRACTORY ANTISYNTHETASE SYNDROME
    Murphy, Sean M.
    Lilleker, James B.
    Chinoy, Hector
    Helliwell, Philip
    RHEUMATOLOGY, 2016, 55 : 63 - 63
  • [32] Severe Immune Checkpoint Inhibitor Hepatitis: Case Report
    Aliyev, Nurlan
    Chaisidhivej, Natapat
    Reif, Meagan S.
    Bhat, Romana A.
    Khoury, Nathalie
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S2894 - S2895
  • [33] A Case of Fatal Immune Checkpoint Inhibitor Mediated Hepatitis
    Schroeder, Shannon
    Medici, Valentina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S1134 - S1135
  • [34] Steroid-refractory immune checkpoint inhibitor (ICI) hepatitis and ICI rechallenge: A systematic review and meta-analysis
    Hwang, Soo Young
    Hsieh, Pinghsin
    Zhang, Wei
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (10)
  • [35] Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritis
    Obeid, M.
    Petit, P-F.
    Latifyan, S.
    Daoudlarian, D.
    Joo, V.
    Bartolini, R.
    Bouchaab, H.
    Alfonso, N. Mederos
    Abdelhamid, K.
    Doms, J.
    Ferahta, N.
    Mencarelli, L.
    Stravodimou, A.
    Shabafrouz, K.
    Pantaleo, G.
    Peters, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S699 - S700
  • [36] Severe Refractory Checkpoint Inhibitor-Related Hepatitis Reversed With Anti-Thymocyte Globulin and n-Acetylcysteine
    Motomura, Douglas
    Baetz, Tara
    Grin, Andrea
    Flemming, Jennifer A.
    HEPATOLOGY, 2020, 72 (06) : 2235 - 2238
  • [37] Use of verapamil as a potential P-glycoprotein inhibitor in patients with refractory epilepsy
    McAuley, JW
    Summers, MA
    Moore, JL
    Long, L
    Shneker, BF
    EPILEPSIA, 2004, 45 : 124 - 125
  • [38] CMV coinfection in treatment refractory immune checkpoint inhibitor colitis
    Harris, Kevin B.
    Funchain, Pauline
    Baggott, Brian B.
    BMJ CASE REPORTS, 2020, 13 (05)
  • [39] Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy
    Summers, MA
    Moore, JL
    McAuley, JW
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (10) : 1631 - 1634
  • [40] Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy
    Lancelot, Moira
    Miller, Maureen J.
    Roback, John
    Stowell, Sean R.
    TRANSFUSION, 2021, 61 (01) : 322 - 328
12345